External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

Thermo Fisher Scientific Inc / Equity Bottom-Up

<ul><li>Thermo Fisher, distinguished by its extensive portfolio of products and services, stands as a global leader in life science services.</li><li>We are confident in the long-term prospects of Thermo Fisher as a global leader in life sciences industry, backed by its economies of scale, strong industry consolidation capabilities and its end-to-end platform amid the expected turnaround in client destocking and biotech funding.</li><li>We initiate coverage on the stock with a BUY rating and TP of US$670.00.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Thermo Fisher, distinguished by its extensive portfolio of products and services, stands as a global leader in life science services.We are confident in the long-term prospects of Thermo Fisher as a global leader in life sciences industry, backed by its economies of scale, strong industry consolidation capabilities and its end-to-end platform amid the expected turnaround in client destocking and biotech funding.We initiate coverage on the stock with a BUY rating and TP of US$670.00.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Thermo Fisher (TMO US) - A Global Leader in Life Sciences with Favourable Industry Trends

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>Thermo Fisher Scientific Inc. recently disclosed their financial results for the second quarter of 2024, which provide a mixed picture, illustrating both strengths and weaknesses in their performance.</li><li>Starting with the positives, Thermo Fisher experienced a solid revenue posting of $10.54 billion for the quarter, alongside an adjusted operating income of $2.35 billion.</li><li>The adjusted operating margin also saw a notable increase to 22.3%, reflecting a refined operational efficiency.</li></ul>

Thermo Fisher Scientific Inc. recently disclosed their financial results for the second quarter of 2024, which provide a mixed picture, illustrating both strengths and weaknesses in their performance.Starting with the positives, Thermo Fisher experienced a solid revenue posting of $10.54 billion for the quarter, alongside an adjusted operating income of $2.35 billion.The adjusted operating margin also saw a notable increase to 22.3%, reflecting a refined operational efficiency.

Thermo Fisher Scientific Inc.: What Is The Framework Behind Their Market Positioning and Competitive Differentiation? - Major Drivers

<ul><li>Thermo Fisher Scientific posted a strong start to the year, with the first-quarter revenue reaching $10.34 billion and an increase of 2% year-over-year in adjusted EPS, to $5.11 per share.</li><li>The robust financial performance was primarily driven by strong operational discipline, superior commercial execution, and its effective growth strategy.</li><li>The company managed to beat their expectations which is reflected in the raised guidance, setting the stage for strong performance in 2024.</li></ul>

Thermo Fisher Scientific posted a strong start to the year, with the first-quarter revenue reaching $10.34 billion and an increase of 2% year-over-year in adjusted EPS, to $5.11 per share.The robust financial performance was primarily driven by strong operational discipline, superior commercial execution, and its effective growth strategy.The company managed to beat their expectations which is reflected in the raised guidance, setting the stage for strong performance in 2024.

Thermo Fisher Scientific: What Is Their Long-Term Growth Strategy Towards Market Share Expansion? - Major Drivers

<ul><li>Thermo Fisher Scientific was able to engage in strong execution and display solid operational discipline in 2023.</li><li>For that year, the company reported a revenue of $42.9 billion, an adjusted operating income of $9.81 billion and adjusted earnings per share of $21.55.</li><li>Thermo Fisher Scientific attributes these achievements to its efforts of delivering differentiated short-term performance while also strengthening its long-term competitive position.</li></ul>

Thermo Fisher Scientific was able to engage in strong execution and display solid operational discipline in 2023.For that year, the company reported a revenue of $42.9 billion, an adjusted operating income of $9.81 billion and adjusted earnings per share of $21.55.Thermo Fisher Scientific attributes these achievements to its efforts of delivering differentiated short-term performance while also strengthening its long-term competitive position.

Thermo Fisher Scientific: 6 Major Factors Driving Its Growth In 2024! - Financial Forecasts

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>Innovation data suggests that <a href="https://www.smartkarma.com/entities/bayer-ag" target="_blank" data-smartkarma-citation="entities:26881:1" rel="noopener">Bayer AG (BAYN GY)</a> has an almost monopoly stake in agriculture-related microbial, followed by <a href="https://www.smartkarma.com/entities/dupont-de-nemours-inc" target="_blank" data-smartkarma-citation="entities:9239:1" rel="noopener">DuPont (DD US)</a> </li>
<li>In non-ag microbial space <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a>,  <a href="https://www.smartkarma.com/entities/codexis-inc" target="_blank" data-smartkarma-citation="entities:26400:1" rel="noopener">Codexis Inc (CDXS US)</a>,  <a href="https://www.smartkarma.com/entities/regeneron-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:9167:1" rel="noopener">Regeneron Pharmaceuticals (REGN US),</a><a href="https://www.smartkarma.com/entities/immatics-nv" target="_blank" data-smartkarma-citation="entities:33092:1" rel="noopener">Immatics NV (IMTX US)</a> lead the field</li>
<li>In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, <a href="https://www.smartkarma.com/entities/johnson-johnson" target="_blank" data-smartkarma-citation="entities:1132:1" rel="noopener">Johnson &amp; Johnson (JNJ US)</a>, and <a href="https://www.smartkarma.com/entities/pfizer-inc" target="_blank" data-smartkarma-citation="entities:1131:1" rel="noopener">Pfizer Inc (PFE US) </a>lead</li>
</ul>


Innovation data suggests that Bayer AG (BAYN GY) has an almost monopoly stake in agriculture-related microbial, followed by DuPont (DD US) 
In non-ag microbial space Moderna Inc (MRNA US),  Codexis Inc (CDXS US),  Regeneron Pharmaceuticals (REGN US),Immatics NV (IMTX US) lead the field
In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, Johnson &amp; Johnson (JNJ US), and Pfizer Inc (PFE US) lead


Insights from Data Mining Technical Publications - Microbes - Bacteriophages

United States

Thermo Fisher Scientific, Inc. manufactures scientific instruments, consumables, and chemicals.  The Company offers analytical instruments, laboratory equipment, software, services, consumables, reagents, chemicals, and supplies to pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Thermo Fisher Scientific Inc (TMO US)

Thermo Fisher (TMO US) - A Global Leader in Life Sciences with Favourable Industry Trends

Thermo Fisher, distinguished by its extensive portfolio of products and services, stands as a global leader in life science services.

CMB International

Thermo Fisher Scientific Inc.: What Is The Framework Behind Their Market Positioning and Competitive Differentiation? - Major Drivers

Thermo Fisher Scientific Inc. recently disclosed their financial results for the second quarter of 2024, which provide a mixed picture,...

Baptista Research

Thermo Fisher Scientific: 6 Major Factors Driving Its Growth In 2024! - Financial Forecasts

Thermo Fisher Scientific was able to engage in strong execution and display solid operational discipline in 2023. For that year, the company...

Baptista Research

Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Innovations are modifying and harnessing microbes for new uses in agriculture, industry, and as potential new therapeutics to replace or...

Pyari Menon

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Thermo Fisher (TMO US) - A Global Leader in Life Sciences with Favourable Industry Trends

Thermo Fisher, distinguished by its extensive portfolio of products and services, stands as a global leader in life science services.

CMB International

Thermo Fisher Scientific Inc.: What Is The Framework Behind Their Market Positioning and Competitive Differentiation? - Major Drivers

Thermo Fisher Scientific Inc. recently disclosed their financial results for the second quarter of 2024, which provide a mixed picture,...

Baptista Research

Thermo Fisher Scientific: What Is Their Long-Term Growth Strategy Towards Market Share Expansion? - Major Drivers

Thermo Fisher Scientific posted a strong start to the year, with the first-quarter revenue reaching $10.34 billion and an increase of 2%...

Baptista Research

Thermo Fisher Scientific: 6 Major Factors Driving Its Growth In 2024! - Financial Forecasts

Thermo Fisher Scientific was able to engage in strong execution and display solid operational discipline in 2023. For that year, the company...

Baptista Research

Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Innovations are modifying and harnessing microbes for new uses in agriculture, industry, and as potential new therapeutics to replace or...

Pyari Menon